GLP-1-Based Pharmacotherapies and Skeletal Muscle Health in Obesity: A Narrative Review of Body Composition, Muscle Function, and Sarcopenia-Related Outcomes
Background: Obesity is associated with impaired skeletal muscle health and sarcopenic obesity. GLP-1-based pharmacotherapies induce weight loss, but accompanying reductions in fat-free or lean mass raise concerns about skeletal muscle loss. Conversely, reductions in adiposity, inflammation, insulin resistance, and intr...